US stock futures dip as Nvidia earnings spark little cheer
PRINCETON, N.J. – ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), a diversified biopharmaceutical company with a market capitalization of $1.3 billion and impressive revenue growth of 26.2% over the last twelve months, has announced the market launch of its Nitazoxanide Tablets, 500 mg, a generic version of the reference listed drug Alinia®. This development adds to the company’s portfolio of generic pharmaceuticals.
According to IQVIA data with a December 2024 moving annual total (MAT), the U.S. annual sales for Nitazoxanide Tablets are estimated at approximately $36.1 million. The release of this generic drug is part of ANI’s commitment to providing affordable, high-quality medicines, as emphasized by Nikhil Lalwani, President and CEO of ANI Pharmaceuticals. According to InvestingPro analysis, ANI maintains strong liquidity with a current ratio of 2.72, indicating robust operational capacity for new product launches.
ANI Pharmaceuticals operates in the biopharmaceutical industry with a focus on rare diseases, generics, and branded medications. The company’s mission is to serve patients and improve lives through the development, manufacturing, and commercialization of innovative and high-quality therapeutics. InvestingPro data shows the company maintains a "GREAT" overall financial health score, with analysts expecting profitability improvement in the coming year.
In partnership with Biophore India Pharmaceuticals Pvt. Ltd., ANI aims to address the needs of patients relying on these essential medications. Biophore, known for its development and manufacturing of niche pharmaceutical products, supports ANI’s initiative by providing high-quality medicines.
The launch of Nitazoxanide Tablets signifies ANI’s strategic growth in the generics market and its dedication to expanding its product offerings in areas with limited competition. The company’s broader portfolio includes products in ophthalmology, rheumatology, nephrology, neurology, and pulmonology. Five analysts have recently revised their earnings expectations upward, suggesting strong growth potential. Discover more insights about ANI’s market position and growth prospects in the comprehensive Pro Research Report, available exclusively on InvestingPro.
ANI Pharmaceuticals and Biophore’s collaboration reflects a shared commitment to patient care and the provision of accessible treatments. This announcement is based on a press release statement and provides insights into the company’s latest efforts to meet market demands for generic pharmaceuticals.
In other recent news, ANI Pharmaceuticals has settled a royalty obligation with SWK Funding LLC for $17.25 million, ending payments related to ILUVIEN and YUTIQ revenues from January 2025. This strategic move was financed through ANI’s cash reserves, aiming to enhance financial flexibility and growth potential. The U.S. FDA has also approved an updated label for ILUVIEN, expanding its use to treat chronic non-infectious uveitis affecting the posterior segment of the eye. ANI plans to market this updated version in the U.S. later this year, with the drug already approved in several European countries.
Analyst activity around ANI Pharmaceuticals includes Jefferies initiating coverage with a Buy rating and an $80 price target, citing momentum from Cortrophin Gel and generic offerings. JPMorgan has also started coverage with an Overweight rating and an $85 target, highlighting the company’s strong branded and generic product portfolio. Meanwhile, Truist Securities maintains a Hold rating with a $62 target, focusing on the company’s strategic realignment of its Rare Disease and Brands segment. These developments reflect the varied analyst perspectives on ANI’s potential growth and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.